Analysts Offer Predictions for CNTB FY2029 Earnings

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Connect Biopharma in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.19) for the year. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.20) per share.

Connect Biopharma Stock Performance

Connect Biopharma stock opened at $1.05 on Friday. The firm has a 50-day moving average of $1.08 and a 200-day moving average of $1.15. Connect Biopharma has a one year low of $0.91 and a one year high of $2.66.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. BML Capital Management LLC increased its position in shares of Connect Biopharma by 2.4% during the 3rd quarter. BML Capital Management LLC now owns 2,093,232 shares of the company’s stock worth $3,014,000 after purchasing an additional 49,984 shares during the last quarter. Choreo LLC bought a new position in shares of Connect Biopharma in the fourth quarter valued at $204,000. Callan Capital LLC increased its holdings in Connect Biopharma by 91.3% during the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after buying an additional 38,177 shares during the last quarter. Finally, Catalina Capital Group LLC acquired a new position in Connect Biopharma during the fourth quarter worth $66,000. 58.72% of the stock is owned by institutional investors and hedge funds.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.